Literature DB >> 16054339

Normal and abnormal mechanisms of gene splicing and relevance to inherited skin diseases.

Vesarat Wessagowit1, Vijay K Nalla, Peter K Rogan, John A McGrath.   

Abstract

The process of excising introns from pre-mRNA complexes is directed by specific genomic DNA sequences at intron-exon borders known as splice sites. These regions contain well-conserved motifs which allow the splicing process to proceed in a regulated and structured manner. However, as well as conventional splicing, several genes have the inherent capacity to undergo alternative splicing, thus allowing synthesis of multiple gene transcripts, perhaps with different functional properties. Within the human genome, therefore, through alternative splicing, it is possible to generate over 100,000 physiological gene products from the 35,000 or so known genes. Abnormalities in normal or alternative splicing, however, account for about 15% of all inherited single gene disorders, including many with a skin phenotype. These splicing abnormalities may arise through inherited mutations in constitutive splice sites or other critical intronic or exonic regions. This review article examines the process of normal intron-exon splicing, as well as what is known about alternative splicing of human genes. The review then addresses pathological disruption of normal intron-exon splicing that leads to inherited skin diseases, either resulting from mutations in sequences that have a direct influence on splicing or that generate cryptic splice sites. Examples of aberrant splicing, especially for the COL7A1 gene in patients with dystrophic epidermolysis bullosa, are discussed and illustrated. The review also examines a number of recently introduced computational tools that can be used to predict whether genomic DNA sequences changes may affect splice site selection and how robust the influence of such mutations might be on splicing.

Entities:  

Mesh:

Year:  2005        PMID: 16054339      PMCID: PMC1351063          DOI: 10.1016/j.jdermsci.2005.05.006

Source DB:  PubMed          Journal:  J Dermatol Sci        ISSN: 0923-1811            Impact factor:   4.563


  34 in total

1.  Genotype-phenotype correlation in recessive dystrophic epidermolysis bullosa: when missense doesn't make sense.

Authors:  Vesarat Wessagowit; Soo-Chan Kim; Se Woong Oh; John A McGrath
Journal:  J Invest Dermatol       Date:  2005-04       Impact factor: 8.551

2.  Evolutionary fates and origins of U12-type introns.

Authors:  C B Burge; R A Padgett; P A Sharp
Journal:  Mol Cell       Date:  1998-12       Impact factor: 17.970

3.  Comparative mutation detection screening of the type VII collagen gene (COL7A1) using the protein truncation test, fluorescent chemical cleavage of mismatch, and conformation sensitive gel electrophoresis.

Authors:  N V Whittock; G H Ashton; R Mohammedi; J E Mellerio; C G Mathew; S J Abbs; R A Eady; J A McGrath
Journal:  J Invest Dermatol       Date:  1999-10       Impact factor: 8.551

4.  Automated splicing mutation analysis by information theory.

Authors:  Vijay K Nalla; Peter K Rogan
Journal:  Hum Mutat       Date:  2005-04       Impact factor: 4.878

5.  Deletion of a branch-point consensus sequence in the LMX1B gene causes exon skipping in a family with nail patella syndrome.

Authors:  J D Hamlington; M V Clough; J A Dunston; I McIntosh
Journal:  Eur J Hum Genet       Date:  2000-04       Impact factor: 4.246

6.  Mutations affecting mRNA splicing are the most common molecular defects in patients with neurofibromatosis type 1.

Authors:  E Ars; E Serra; J García; H Kruyer; A Gaona; C Lázaro; X Estivill
Journal:  Hum Mol Genet       Date:  2000-01-22       Impact factor: 6.150

7.  Information analysis of human splice site mutations.

Authors:  P K Rogan; B M Faux; T D Schneider
Journal:  Hum Mutat       Date:  1998       Impact factor: 4.878

8.  A point mutation in an intronic branch site results in aberrant splicing of COL5A1 and in Ehlers-Danlos syndrome type II in two British families.

Authors:  N P Burrows; A C Nicholls; A J Richards; C Luccarini; J B Harrison; J R Yates; F M Pope
Journal:  Am J Hum Genet       Date:  1998-08       Impact factor: 11.025

Review 9.  Mutations that alter RNA splicing of the human HPRT gene: a review of the spectrum.

Authors:  J P O'Neill; P K Rogan; N Cariello; J A Nicklas
Journal:  Mutat Res       Date:  1998-11       Impact factor: 2.433

10.  Missense and silent tau gene mutations cause frontotemporal dementia with parkinsonism-chromosome 17 type, by affecting multiple alternative RNA splicing regulatory elements.

Authors:  I D'Souza; P Poorkaj; M Hong; D Nochlin; V M Lee; T D Bird; G D Schellenberg
Journal:  Proc Natl Acad Sci U S A       Date:  1999-05-11       Impact factor: 11.205

View more
  11 in total

1.  Restriction of porcine endogenous retrovirus by porcine APOBEC3 cytidine deaminases.

Authors:  Eva Dörrschuck; Nicole Fischer; Ignacio G Bravo; Kay-Martin Hanschmann; Heidi Kuiper; Andreas Spötter; Ronny Möller; Klaus Cichutek; Carsten Münk; Ralf R Tönjes
Journal:  J Virol       Date:  2011-02-09       Impact factor: 5.103

2.  Revertant mosaicism in junctional epidermolysis bullosa due to multiple correcting second-site mutations in LAMB3.

Authors:  Anna M G Pasmooij; Hendri H Pas; Maria C Bolling; Marcel F Jonkman
Journal:  J Clin Invest       Date:  2007-05       Impact factor: 14.808

3.  Identification of eight novel mutations of the acid alpha-glucosidase gene causing the infantile or juvenile form of glycogen storage disease type II.

Authors:  L Wan; C-C Lee; C-M Hsu; W-L Hwu; C-C Yang; C-H Tsai; F-J Tsai
Journal:  J Neurol       Date:  2008-05-06       Impact factor: 4.849

4.  A COL2A1 gene polymorphism is related with advanced stages of osteoarthritis of the knee in Mexican Mestizo population.

Authors:  Arturo Gálvez-Rosas; Celia González-Huerta; Verónica Marusa Borgonio-Cuadra; Carolina Duarte-Salazár; Lorena Lara-Alvarado; María de los Angeles Soria-Bastida; Socorro Cortés-González; Eva Ramón-Gallegos; Antonio Miranda-Duarte
Journal:  Rheumatol Int       Date:  2009-09-16       Impact factor: 2.631

Review 5.  Interpretation of mRNA splicing mutations in genetic disease: review of the literature and guidelines for information-theoretical analysis.

Authors:  Natasha Caminsky; Eliseos J Mucaki; Peter K Rogan
Journal:  F1000Res       Date:  2014-11-18

6.  Increasing the relative expression of endogenous non-coding Steroid Receptor RNA Activator (SRA) in human breast cancer cells using modified oligonucleotides.

Authors:  Charlton Cooper; Jimin Guo; Yi Yan; Shilpa Chooniedass-Kothari; Florent Hube; Mohammad K Hamedani; Leigh C Murphy; Yvonne Myal; Etienne Leygue
Journal:  Nucleic Acids Res       Date:  2009-05-29       Impact factor: 16.971

7.  Identification and characterization of alternative exon usage linked glioblastoma multiforme survival.

Authors:  Ahmed Sadeque; Nicola Vl Serão; Bruce R Southey; Kristin R Delfino; Sandra L Rodriguez-Zas
Journal:  BMC Med Genomics       Date:  2012-12-04       Impact factor: 3.063

8.  Truncation of retinoschisin protein associated with a novel splice site mutation in the RS1 gene.

Authors:  Balázs Lesch; Viktória Szabó; Melinda Kánya; Balázs Varsányi; Gábor M Somfai; János Hargitai; Rita Vámos; Orsolya Fiedler; Agnes Farkas
Journal:  Mol Vis       Date:  2008-08-25       Impact factor: 2.367

9.  A luteinizing hormone receptor intronic variant is significantly associated with decreased risk of Alzheimer's disease in males carrying an apolipoprotein E epsilon4 allele.

Authors:  Ryan J Haasl; M Reza Ahmadi; Sivan Vadakkadath Meethal; Carey E Gleason; Sterling C Johnson; Sanjay Asthana; Richard L Bowen; Craig S Atwood
Journal:  BMC Med Genet       Date:  2008-04-25       Impact factor: 2.103

10.  New Antimicrobial Potential and Structural Properties of PAFB: A Cationic, Cysteine-Rich Protein from Penicillium chrysogenum Q176.

Authors:  Anna Huber; Dorottya Hajdu; Doris Bratschun-Khan; Zoltán Gáspári; Mihayl Varbanov; Stéphanie Philippot; Ádám Fizil; András Czajlik; Zoltán Kele; Christoph Sonderegger; László Galgóczy; Andrea Bodor; Florentine Marx; Gyula Batta
Journal:  Sci Rep       Date:  2018-01-29       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.